TON - April 2021 Vol 14, No 2
In this issue of The Oncology Nurse-APN/PA (TON), we feature a variety of articles designed to help our readers stay informed on timely issues facing nurses, navigators, and advanced practice providers as they care for their patients with cancer.
Northside Hospital Cancer Institute is Georgia’s largest and most comprehensive community cancer care provider. With a network of more than 55 cancer locations and the highest number of board-certified oncologists in the state, it diagnoses and treats more new cases of cancer each year than any other community cancer program in Georgia.
A diagnosis of breast cancer can cause stress and depression, especially in younger women. According to findings from a recent clinical trial, behavioral interventions may help decrease symptoms of depression and reduce anxiety, fatigue, and sleep disturbances in younger breast cancer survivors.
The HER2-targeted bispecific investigational antibody zanidatamab, either as monotherapy or in combination with chemotherapy, has shown promising antitumor activity in an ongoing clinical trial of patients with HER2-expressing biliary tract cancer or gastroesophageal adenocarcinoma.
Physicians May Underestimate the Severity of Radiation-Associated Symptoms in Some Patients with Breast Cancer
Physicians often fail to perceive radiation-associated symptoms and the severity of those symptoms, according to the results of a large observational study that compared the reports of patients with breast cancer with physicians’ assessments of 4 common radiation-associated symptoms.
Many Postmenopausal Women with HR-Positive, HER2-Negative, Early-Stage Breast Cancer May Be Able to Skip Additional Chemotherapy
Results of the SWOG S1007 RxPONDER clinical trial suggest that many postmenopausal women with early-stage hormone receptor (HR)-positive, human epidermal growth receptor 2 (HER2)-negative breast cancer, and 1 to 3 positive axillary lymph nodes may be able to avoid adjuvant chemotherapy.
Final results from the phase 3 clinical trial ClarIDHy showed that ivosidenib (Tibsovo), a first-in-class oral inhibitor of isocitrate dehydrogenase 1 (IDH1) mutation, prolonged the median overall survival (OS) in patients with previously treated advanced cholangiocarcinoma (CCA) and IDH1 mutation.
Page 1 of 2
Results 1 - 10 of 14
Results 1 - 10 of 14